首页> 美国卫生研究院文献>other >Personalised chemotherapy based on tumour marker decline in poor-prognosis germ-cell tumours: results of the GETUG 13 phase III trial

【2h】

Personalised chemotherapy based on tumour marker decline in poor-prognosis germ-cell tumours: results of the GETUG 13 phase III trial

机译：预后不良的生殖细胞肿瘤中基于肿瘤标志物下降的个性化化疗：GETUG 13 III期试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPoor-prognosis germ-cell tumours (GCT) are associated with only a 50% cure rate. Our hypothesis was that treatment intensification based on an early tumour marker decline will improve progression-free survival (PFS).

机译：背景预后不良的生殖细胞肿瘤（GCT）仅与50％的治愈率相关。我们的假设是基于早期肿瘤标志物下降的治疗强化将改善无进展生存期（PFS）。

著录项

期刊名称 other
作者
Karim Fizazi Prof.; Lance Pagliaro; Agnes Laplanche; Aude Fléchon; Josef Mardiak Prof.; Lionnel Geoffrois; Pierre Kerbrat Prof.; Christine Chevreau; Remy Delva; Frederic Rolland; Christine Theodore; Guilhem Roubaud; Gwenaëlle Gravis; Jean-Christophe Eymard; Jean-Pierre Malhaire; Claude Linassier Prof.; Muriel Habibian; Anne-Laure Martin; Florence Journeau; Maria Reckova; Christopher Logothetis Prof.; Stephane Culine Prof.;
展开▼
作者单位

展开▼
年(卷),期 -1(15),13
年度 -1
页码 1442–1450
总页数 23
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases [J] . Loriot Y., Pagliaro L., Flechon A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：Getug 13试验中预后贫病种细胞肿瘤的复发模式：对脑转移评估的影响
2. Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.' by Loriot and colleagues [J] . Alifrangis Constantine, Wilson Peter, Shamash Jonathan European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：致编辑的信：中枢神经系统复发率和剂量强化在风险转移性毒细胞肿瘤中 - 评论：'Getug-13试验中预后差异细胞肿瘤的复发模式：对脑转移评估的影响。 ' 由Loriot和同事
3. A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604) [J] . Huddart Robert A., Gabe Rhian, Cafferty Fay H., European urology . 2015,第3期

机译：预后不良的生殖细胞肿瘤的密集诱导化学疗法（CBOP / BEP）和标准BEP的随机2期试验（MRC TE23，CRUK 05/014，ISRCTN 53643604）
4. Imaging-based classification algorithms on clinical trial data with injected tumour responses [C] . Yunpeng Li, Porter Emily, Coates Mark European Conference on Antennas and Propagation . 2015

机译：基于成像的基于分类算法的注射有肿瘤反应的临床试验数据
5. A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23 CRUK 05/014 ISRCTN 53643604) [O] . Robert A. Huddart, Rhian Gabe, Fay H. Cafferty, -1

机译：预后不良的生殖细胞肿瘤的密集诱导化学疗法（CBOP / BEP）和标准BEP的随机2期试验（MRC TE23CRUK 05/014ISRCTN 53643604）
6. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial [O] . Karim Fizazi, Lance Pagliaro, Agnes Laplanche, 2014

机译：基于肿瘤标志物的个性化化疗在差的预后细胞肿瘤差（Getug 13）：3，多期，随机试验

Personalised chemotherapy based on tumour marker decline in poor-prognosis germ-cell tumours: results of the GETUG 13 phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅